Deals

A journey began eight years ago continues for Doc Generici – now rebranded as DOC Pharma – as it continues to diversify its offerings beyond conventional generic prescription pharmaceuticals.

For In Vivo's 17th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

With new Phase I/Ib results in kidney cancer, the HIF-2a inhibitor outshines Merck’s Welireg, but longtime Arcus partner Gilead decided not to exercise its option for casdatifan.

In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.

As Biogen’s MS revenue continues its multi-year decline, the slow return to growth raises concerns about the company’s pipeline – but CEO Christopher Viehbacher said all is on track.

During Q4, biopharmas brought in an aggregate $16.8bn in financing and device company fundraising totaled $2.3bn; while in vitro diagnostic firms and research tools players raised $294m.

CEO Christopher Viehbacher has said repeatedly that Biogen will build its pipeline internally and through deals, and Grogan reshuffled the research organization with that in mind.

PCH announces 2.7 % reported growth to $290.3m in revenues for its latest quarter. Fleet line extensions don’t the brand against fiber product lines such as Metamucil and Benefiber. Licenses all markets for Hydralyte outside US. Two more Clear Eyes suppliers to be added as current pair repair their processes.

An interactive look at pharma, medtech and diagnostics deals made during January 2025. Data courtesy of Biomedtracker.